Here's what's in our Biotechnology market report
In our biotechnology market deck, you will find everything you need to understand the market
SUMMARY
Here's what's in our Biotechnology market report: a 210+ page, 12-section research deck covering market definition, market size, technologies, startups, funding, investors, business models, customers, risks, competitors and company strategies.
The scope is deliberately defined before the numbers are calculated. We include modern biological science and engineering used to improve medical or life-science outcomes, while routine healthcare delivery and conventional pharmaceuticals sit outside the core scope.
That scope discipline explains why our market-size section can differ from headline figures elsewhere. We build an estimate from the market definition, compare it with outside research and show the assumptions instead of treating one published CAGR as settled fact.
The technology section separates what is commercially real from what is still a bet. Gene therapy, mRNA, CRISPR, biomanufacturing, computational biology and other platforms are mapped with a distinction between approved technologies, clinical-stage work and earlier research.
The competitive view is broader than a list of famous pharma names. Established companies such as Moderna, BioNTech, Genentech and Regeneron sit alongside younger biotech companies when the evidence suggests they could become meaningful competitors.
Funding is used as a pattern detector, not a leaderboard. We look at where large rounds keep happening, where investors are becoming more selective and what strategic deals reveal about the assets pharmaceutical companies are still willing to pay heavily for.
The business-model section is one of the more practical parts of the deck. Licensing, milestone payments, royalties, platform partnerships, CDMO services and direct product sales can create very different economics even when the underlying science looks equally impressive.
The report spends a lot of time on the places where biotech businesses break. Clinical failure is only one risk; capital intensity, CMC work, manufacturing, patents, regulation, reimbursement and weak commercialization choices can kill an otherwise promising company.
The global coverage follows activity rather than geography for geography's sake. The US gets substantial attention, with Europe, Asia and other ecosystems included where companies, funding or strategic activity materially change the picture.
This is mainly a decision-making report for founders, investors, operators and strategy teams, not a beginner's introduction to biotech. It is delivered digitally in English, starts at $49 and is designed so readers can jump directly to the section they need instead of reading 210+ pages in order.
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Is this Biotechnology market report actually up to date?
The current Biotechnology Market Report is a recent 2026 report built around the latest market, company, technology, funding and investor signals we have collected.
Biotech moves too fast for a report to stay useful for long without updates. Clinical results can change a company’s outlook, funding rounds can shift investor attention, and new technologies can move from research into trials surprisingly quickly.
So we keep refreshing the parts of the report where recency matters most instead of leaving buyers with a static snapshot.
What exactly is inside the Biotechnology Market Report?
The Biotechnology Market Report is a 210+ page research deck covering market size, technologies, startups, funding, investors, business models, risks, competitors and company strategies.
We split the report into 12 core sections, so someone can go from understanding what we count as biotechnology to seeing where the money is going, which companies matter, which technologies are moving forward and where startups tend to get stuck.
| Section | What we cover |
|---|---|
| Market Definition | What we include and exclude from biotechnology |
| Market Opportunity | Why the market is interesting now |
| Market Size | Current size, growth potential and assumptions |
| Pain Points | Who the customers are and what they need |
| Tech & Infra | Technologies, platforms and enabling infrastructure |
| Value Creation | How biotech companies make money |
| Market Challenges | What can slow the market down |
| Growth Drivers | What could push adoption higher |
| Investor Bets | Funding activity and where capital is moving |
| Top Players | Startups, established companies and market maps |
| Startup Killers | Common reasons biotech startups fail |
| Startup Strategies | What successful biotech companies tend to do better |
As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward
What does this Biotechnology report actually count as biotech?
The Biotechnology Market Report uses a defined scope so the market size does not get inflated by throwing every healthcare company into the same bucket.
We include products and services that use modern biological science and engineering to improve medical or life-science outcomes. That covers areas such as biopharma R&D, biologics, cell and gene therapies, vaccines, molecular diagnostics, research tools, reagents and technologies used to generate or analyze biological data.
Routine healthcare delivery and conventional pharmaceuticals that do not rely on biotechnology are outside the core scope. Agriculture and industrial biotech are only included when they are directly relevant to the analysis.
That definition changes the market numbers more than most people expect. Two biotech reports can look completely different simply because they count different things.
If you want more recent data on this point, please see our latest biotechnology market report.
Does the Biotechnology report include market size and forecasts?
Yes. The Biotechnology Market Report includes current market sizing, forward-looking growth estimates and the assumptions behind those numbers.
We define the market first, build our own estimate, compare it with outside research and show the logic behind the result instead of just picking one market-size figure from the internet and repeating it.
In biotech, published market estimates can vary wildly depending on whether a source includes pharmaceuticals, diagnostics, research tools, agricultural biotech or other adjacent markets.
The report also looks at what would need to happen for future growth estimates to make sense, rather than treating a CAGR as a fact that will automatically come true.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Does the Biotechnology report cover the technologies that matter right now?
The Biotechnology Market Report covers the technologies and platforms that are shaping the market now, including both established approaches and newer ones moving through development.
We look at areas such as gene therapy, mRNA platforms, CRISPR and gene editing, biomanufacturing, computational biology and other technologies that support modern biotech R&D and commercialization.
We also separate technologies that are already approved from those still in trials or earlier-stage research. That gives buyers a much better sense of what is commercially real today and what is still mostly a bet on the future.
Does the Biotechnology report include startups, or mostly big pharma companies?
The Biotechnology Market Report includes both emerging biotech startups and established companies, so the competitive picture is not dominated by the biggest pharmaceutical groups.
We use company grids and ecosystem maps to show where businesses sit across different parts of the market, including therapeutic platforms, research technologies and newer biotech approaches.
Some of the most interesting biotech companies are still relatively small when they first start attracting serious investor or strategic attention, so leaving them out would distort the picture.
This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology
Does the Biotechnology report show which companies are actually leading?
The Biotechnology Market Report maps the companies that currently matter most across different parts of the market and explains why they stand out.
We cover established names such as Moderna, BioNTech, Genentech and Regeneron, but the report goes further than listing famous companies. We look at the capabilities, technologies, partnerships and positions that make certain businesses stronger than the rest.
We also include younger companies where the signals are strong enough to suggest they could become important competitors.
Does the Biotechnology report include recent funding rounds and big investments?
The Biotechnology Market Report tracks recent biotech funding activity, including major rounds and the areas where investors are still willing to put serious money to work.
We look at which companies are raising capital, which therapeutic areas or platforms keep attracting funding and where investors have become more selective.
A raw list of funding rounds is not very useful on its own. We connect those deals so buyers can see patterns in what investors are backing.
The report also uses large acquisitions and strategic transactions as signals when they help show what established pharmaceutical companies are willing to pay for. Deals such as Pfizer’s $43 billion acquisition of Seagen are useful because they reveal how highly certain biotech assets can still be valued even when venture funding gets tighter.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups
Does the Biotechnology report show what biotech investors are betting on now?
The Biotechnology Market Report has a dedicated Investor Bets section that shows where biotech capital is concentrating today.
We compare the types of companies still attracting large rounds, including their therapeutic areas, technologies, development stages and commercial models.
We also watch where investor enthusiasm is cooling. In biotech, that can be just as useful as knowing where money is flowing, especially for founders deciding what to build and investors trying to avoid crowded or weakening areas.
Does the Biotechnology report explain how biotech companies make money?
The Biotechnology Market Report compares the main business models used across biotech, from licensing and royalties to partnerships, services and direct product sales.
Biotech revenue models can look very different from one company to another. Some businesses license technology to larger pharmaceutical groups. Others receive milestone payments, earn royalties, sell research tools, provide development or manufacturing services, or commercialize approved products themselves.
Strong science alone does not tell you whether a company has a good way to capture value, so the report compares these models side by side.
| Business model | How biotech companies make money |
|---|---|
| Licensing | Charging partners for rights to technology or assets |
| Milestone agreements | Payments when development or commercial goals are reached |
| Royalties | Taking a share of future product revenue |
| Platform partnerships | Getting paid through research or drug-discovery collaborations |
| CDMO services | Selling development and manufacturing services |
| Product sales | Selling approved products directly |
This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies
Does the Biotechnology report show who biotech companies are selling to?
The Biotechnology Market Report identifies the main customer groups behind demand and the problems those customers are trying to solve.
Depending on the part of biotech, those buyers can include pharmaceutical companies, healthcare organizations, research institutions and other life-science businesses.
We connect those customer groups with specific pain points, which helps separate ideas with real demand from technologies that may be scientifically interesting but still lack a clear customer.
Does the Biotechnology report cover the risks that could derail the market?
The Biotechnology Market Report covers the major risks that can stop good science from turning into a good business.
Clinical trial failure is an obvious one, but biotech companies can also run into huge capital needs, long development timelines, manufacturing problems, CMC complexity, patent issues, slow regulatory processes and reimbursement resistance after approval.
We cover these risks inside the market challenges and startup analysis rather than treating them as a generic disclaimer at the end of the deck.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market
Does the Biotechnology report cover regulation, clinical trials and manufacturing?
The Biotechnology Market Report covers regulatory pathways, clinical development and manufacturing issues wherever they affect the commercial outlook of a biotech segment.
That includes the practical problems companies can face while moving from research into trials, scaling production, meeting regulatory requirements and preparing a product for real-world use.
For buyers looking at a specific biotech opportunity, these details can change the conclusion completely. A technology can look great on paper and still be a poor business if manufacturing is too difficult or the regulatory path is too long.
Does the Biotechnology report explain why biotech startups fail?
The Biotechnology Market Report looks at recurring failure patterns in biotech startups and compares them with the strategies used by companies that make it further.
Common problems include chasing too many indications, underestimating manufacturing and CMC work, burning through more capital than expected, choosing weak commercial partnerships or assuming positive scientific results will automatically create demand.
The stronger companies tend to make better choices around indication selection, manufacturing, regulatory planning, partnerships and commercialization.
Biotech startup failure is often very specific to the industry, and generic startup advice usually misses the hardest parts.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time
Does the Biotechnology report cover the US, Europe and other biotech markets?
The Biotechnology Market Report takes a global view and includes relevant companies, funding activity and market signals from the US, Europe, Asia and other important biotech ecosystems.
The US naturally gets a lot of attention because so much biotech funding, company formation and pharmaceutical activity happens there. Europe and Asia are also covered where they change the competitive or investment picture.
We do not add country sections just to make the report look broader. Geography is included when it genuinely helps explain where companies, capital or market activity are concentrated.
Where does the Biotechnology report get its data?
The Biotechnology Market Report uses company filings, public datasets, funding databases, industry research, expert input and other established sources.
Important data points and assumptions are sourced inside the deck, so readers can check where a market estimate, company figure or funding signal came from.
That is especially useful in biotechnology because company status, clinical progress and financing data can become outdated quickly or get repeated online without much context.
In our biotechnology market deck, we identify pain points entrepreneurs should prioritize
How does the Biotechnology report handle conflicting market-size numbers?
The Biotechnology Market Report reconciles conflicting market estimates by fixing the market definition first, then comparing multiple sources and building a first-principles estimate.
Two biotech reports can produce completely different numbers while both appearing credible. Often, they are simply measuring different markets.
We make the assumptions visible so buyers can judge whether our biotechnology market size matches the scope they actually care about.
Who is the Biotechnology Market Report really for?
The Biotechnology Market Report is built mainly for founders, investors, operators and strategy teams who need to make a decision about the market rather than just learn the basics.
A founder can use it to understand where opportunities and startup risks are concentrated. An investor can use it to map companies, funding and technologies. A strategy team can use it for competitor research, market entry or partnership work.
Someone looking for a short introduction to biotechnology probably does not need a 210+ page report. It makes more sense when the reader needs enough depth to compare opportunities, companies or market segments.
If you want more recent data on this point, please see our latest biotechnology market report.
This chart, featured in our biotechnology market deck, breaks down revenue across Europe, Asia, North America, Africa, and South America in the biotechnology market
What format is the Biotechnology Market Report delivered in?
The Biotechnology Market Report is a digital research deck in English with more than 210 pages.
We use charts, market maps, company grids and structured sections so readers can jump directly to market size, technologies, competitors, funding or business models without reading the whole report from beginning to end.
The report is delivered digitally after purchase.
How much does the Biotechnology Market Report cost?
The Biotechnology Market Report currently starts at $49 as a one-time purchase, with no subscription required.
The product page offers PRO at $49, PRO+ at $79 and PRO++ at $99. Buyers purchasing several New Market Pitch reports can also use the multi-report discounts shown on the site.
The current listed discount is 20% for two reports and 30% for purchases of five or more reports. The product page also displays a separate 10% order discount.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Where can I buy the latest Biotechnology market report?
You can buy the latest New Market Pitch Biotechnology Market Report directly from NewMarketPitch.com. The report is delivered digitally in English.
The current 2026 Biotechnology Market Report starts at $49 and includes more than 210 pages of biotechnology market data, market sizing, technologies, startups, competitors, funding, investors, business models, risks and company strategies.
For someone looking to buy a recent Biotechnology market research report, a Biotechnology industry report in English or current Biotechnology market data, the report is available directly on the New Market Pitch Biotechnology product page.
In our biotechnology market deck, we like to quantify things to make things easier to understand
